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OBJECTIVES The aim of this study was to compare the use of various noninvasive markers for detecting risk
of life-threatening arrhythmic events in patients with Brugada syndrome.
BACKGROUND The role of conduction disturbance in arrhythmogenesis of the syndrome is controversial,
whereas it is well established that repolarization abnormalities are responsible for arrhythmias.
The value of noninvasive markers reflecting conduction or repolarization abnormalities in
identifying patients at risk for significant arrhythmias has not been shown.
METHODS We assessed late potentials (LP) using signal-averaged electrocardiography (ECG), microvolt
T-wave alternans (TWA), and corrected QT-interval dispersion (QTD) in 44 consecutive
patients who had ECGs showing a pattern of right bundle branch block and ST-segment
elevation in leads V1 to V3 but structurally normal hearts. The patients were compared with
30 normal individuals.
RESULTS Eleven patients were excluded from data analysis because of an absence of ECG manifesta-
tions of Brugada syndrome at the time of the tests. A history of life-threatening events
defined as syncope and aborted sudden death was present in 19 of 33 patients (58%); in 15
of the 19 patients, stimulation induced ventricular fibrillation or polymorphic ventricular
tachycardia. The LP were present in 24 of 33 patients (73%); TWA were present in 5 of 31
patients (16%); and a QTD .50 ms was present in 9 of 33 patients (27%). The incidence of
LP in Brugada patients was significantly (p , 0.0001) higher than in the controls, whereas
incidences of TWA and QTD were not significantly different. Multivariate logistic regression
analysis revealed that the presence of LP had the most significant correlation to the
occurrence of life-threatening events (p 5 0.006).
CONCLUSIONS Late potentials are a noninvasive risk stratifier in patients with Brugada syndrome. These
results may support the idea that conduction disturbance per se is arrhythmogenic. (J Am
Coll Cardiol 2001;37:1628–34) © 2001 by the American College of Cardiology
Brugada syndrome, which is characterized by a pattern of
right bundle branch block (RBBB) and ST-segment eleva-
tion in electrocardiogram (ECG) leads V1 through V3, is
considered to be a primary electrical disease of the heart
caused by a defect in ion channel genes, resulting in
abnormal electrophysiological activity in the right ventricle
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and propensity to malignant tachyarrhythmias; it occurs
particularly frequently in men in Asian countries (1–5). The
mechanisms responsible for the arrhythmogenesis in this
syndrome are currently unknown. Recent studies have
linked the pathogenesis of the ECG manifestations of this
syndrome to heterogeneous loss of the action potential
dome, causing a marked epicardial and transmural disper-
sion of repolarization, which may result in the production of
ST-segment elevation, thus giving rise to phase 2 re-entry
(3,4,6). These observations support the hypothesis that the
mechanism of malignant ventricular arrhythmias in this
syndrome is caused by repolarization abnormality.
Another explanation of arrhythmogenesis in this syn-
drome is the presence of delayed conduction in the right
ventricle (7–10), which may support the conduction abnor-
mality hypothesis. Noninvasive risk stratification markers of
arrhythmic events include late potentials (LP) detected by
signal-averaged electrocardiography (11–13), which reflect a
conduction abnormality, and microvolt-level T-wave alter-
nans (TWA) (13–15) and corrected QT-interval dispersion
(QTD) (16,17), which reflect a repolarization abnormality.
These have been used to identify patients at high risk for
sudden cardiac death or malignant ventricular arrhythmias.
However, the value of these noninvasive markers in identi-
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fying patients at risk for life-threatening ventricular arrhyth-
mias has not been studied in Brugada syndrome.
The aim of the present study was to compare usefulness
of LP, TWA, and QTD for identifying patients with
Brugada syndrome susceptible to life-threatening events
associated with ventricular fibrillation (VF) or polymorphic
ventricular tachycardia (VT). Our results were used to test
the hypothesis that a conduction abnormality marker is
better than repolarization abnormality markers in predicting
patients at high risk in the syndrome and that arrhythmo-
genesis in this syndrome is associated with the conduction
disturbance in the right ventricle.
METHODS
Patient population. A total of 44 consecutive patients who
had an ECG with either persistent or transient RBBB
pattern and ST-segment elevation $0.1 mV (either of a
coved or saddle-back type) in leads V1 to V2 or V3 during
sinus rhythm were entered into this study (Fig. 1). In all
patients studied, a typical widened S-wave and a wide QRS
complex ($120 ms) in the left lateral leads were absent,
suggesting patients did not have a true RBBB (i.e., mimic
RBBB). These patients were treated at Toho University
Ohashi Hospital and Tokyo Metropolitan Hiroo General
Hospital between December 1996 and May 2000. Although
all patients underwent all three noninvasive tests, 11 pa-
tients were excluded from data analysis because of an
absence of characteristic ECG manifestations (an RBBB
pattern and ST-segment elevation in the right chest leads)
for Brugada syndrome at the time of the tests. A total of 33
patients (45 6 14 years, 31 men) were assessed in this study.
Before diagnosing Brugada syndrome, we excluded pa-
tients who had evidence of organic heart disease, including
arrhythmogenic right ventricular cardiomyopathy, myocar-
dial ischemia of the right ventricle, and other infiltrative
cardiomyopathies. These diagnoses were based on echocar-
diography (all 33 patients), coronary angiography with
acetylcholine (25 patients), left or right ventriculography (23
patients), scintigraphy (16 patients), helical CT scan (15
patients), magnetic resonance imaging (14 patients), and
endomyocardial biopsy (9 patients). Therefore, all patients
studied were believed to have structurally normal hearts. No
patient had used antiarrhythmic drugs or had electrolyte
disturbances when the characteristic ECG findings were
identified. The values of LP, TWA, and QTD in patients
with the syndrome were sequentially assessed and com-
pared. These values were also compared to those of normal
individuals who were matched for age and gender.
Measurements of noninvasive risk markers. LATE POTEN-
TIALS BY SIGNAL-AVERAGED ECG. The LP were analyzed
using one of two signal-averaged ECG Systems (Arrhyth-
mia Research Technology 1200EPX or Corazonix Predictor
Unit). The analysis is based on the quantitative time domain
measurements of the filtered vector magnitude of the
orthogonal Frank X, Y, and Z leads. The QRS complexes
($200 beats) were amplified, digitized, averaged, and fil-
tered with a high pass filter (40 Hz). Three parameters were
assessed via a computer algorithm: 1) the filtered QRS
duration (f-QRS); 2) the root mean square voltage of the
terminal 40 ms in the filtered QRS complex (RMS40); and
3) the duration of low-amplitude signals ,40 mV in the
terminal filtered QRS complex (LAS40). In the present
study, LP were considered as positive when two criteria
(RMS40 ,20 mV and LAS40 .38 ms) were met in both
systems.
MICROVOLT T-WAVE ALTERNANS. After LP acquisition,
the patient was kept in the same supine position as during
the signal-averaged ECG recordings, and the orthogonal
Frank X, Y, and Z leads and associated vector magnitude
Figure 1. Twelve-lead electrocardiogram from a patient with a pattern of
right bundle branch block and ST-segment elevation in leads V1 through
V3. The configuration of the ST-segment in leads V1 to V2 is a coved type.
Absence of a widened S-wave and a wide QRS complex in the left lateral
leads suggests that this is not a true right bundle branch block. The QT
interval and the corrected QT interval are normal (408 ms and 414 ms,
respectively).
Abbreviations and Acronyms
ECG 5 electrocardiography
f-QRS 5 filtered QRS duration
LAS40 5 duration of low-amplitude signals ,40 mV
in the terminal filtered QRS complex
LP 5 late potentials
QTc 5 corrected QT interval
QTD 5 corrected QT-interval dispersion
RBBB 5 right bundle branch block
RMS40 5 root mean square voltage of the terminal
40 ms in the filtered QRS complex
TWA 5 T-wave alternans
VF 5 ventricular fibrillation
VM 5 vector magnitude
VT 5 ventricular tachycardia
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(VM), and nine standard ECG leads (aVR, aVL, aVF, V1
through V6) were recorded (13). The presence of TWA was
assessed using a CH2000 System (Cambridge Heart, Bed-
ford, Massachusetts), which allows the detection of micro-
volt electrical alternans of the T wave (J point plus 60 ms
through end of the T wave) using spectral analysis. For the
TWA analysis, a graded bicycle ergometer was used to
increase the heart rate to 110 beats/min, because most
patients have a patient-specific heart rate threshold for the
development of alternans between 80 beats/min and 110
beats/min. The TWA was defined as positive if sustained
alternans (i.e., alternans with a duration $1 min) occurred
at a heart rate #110 beats/min, an alternans voltage $1.9
mV during exercise, and an alternans ratio $3.0 in single
orthogonal leads or two adjacent precordial leads. The
TWA was defined as negative if these criteria were not met
at a heart rate $105 beats/min.
CORRECTED QT-INTERVAL DISPERSION. Just prior to LP
and TWA measurements, the 12-lead ECG was recorded
using a computerized ECG machine (FDX-6521, Fukuda
Denshi, Tokyo, Japan) with newly developed software
(QTD-1, Fukuda Denshi) for QT-interval analysis. The
QT intervals and corrected QT intervals (QTc) for each
lead and QTc dispersion (QTD) were automatically calcu-
lated. In brief, the QT intervals are measured by averaging
beats from similar cycles. A global QRS onset and T-wave
offset are determined in all 12 leads, and then an individual
QT interval is measured for each lead. When the T-waves
were too flat or U-waves were present, these leads were
manually excluded from analysis of the QT interval. The
QT intervals were automatically corrected for heart rate
with Bazett’s formula. The QTc was defined as a mean
value of QTc from 12 leads. The QTD was defined as the
difference between the minimal and maximal QTc
(QTcmax2QTcmin) in any of the 12 ECG leads in which it
could be reliably determined. In the present study, QTD
was considered increased when the dispersion was .50 ms
(18).
Electrophysiologic studies. Programmed ventricular stim-
ulation was performed in all patients with syncopal episodes
or aborted sudden death, and in five patients with no
symptomatic episodes. At the time, the H-V interval was
also measured. The stimulation was performed using up to
triple extrastimuli at cycle lengths of 600 or 500 and 400 ms
and twice the diastolic current threshold delivered from the
right ventricular apex and outflow tract. When VF or
polymorphic VT was not inducible, antiarrhythmic drugs,
including flecainide, pilsicainide, cibenzoline, or procain-
amide, were used. Ventricular fibrillation was defined as a
polymorphic ventricular tachyarrhythmia with an R-R in-
terval #200 ms ($300 beats/min) and hemodynamic de-
compensation requiring cardioversion for termination.
Polymorphic VT was defined as $6 polymorphic consecu-
tive ectopic beats that terminated spontaneously.
Statistical analysis. Data are expressed as the mean 6 SD.
Differences in incidence of the LP, TWA, and increased QTD
between the patient group and the control group were exam-
ined by contingency chi-squared tests, calculating the odds
ratios. Differences in RMS40 (mV), LAS40 (ms), an alternans
voltage (mV), mean QTc (ms), and QTcmax2QTcmin (ms)
between the two groups were examined by unpaired t tests.
Differences in the H-V interval (ms) and the magnitude (mV)
of ST-segment (J-point) elevation between the presence and
the absence of LP were also examined by unpaired t tests. The
magnitude of J-point elevation was measured on enlarged
ECG leads V1 through V3. Univariate analyses using chi-
squared tests evaluated the independent predictive values of the
three noninvasive indices associating susceptibility to life-
threatening events in the patient group. Multivariate logistic
regression analysis was performed using LP as a response
variable and two indices (TWA and QTD) as explanatory
variables. Sensitivity, specificity, positive and negative predic-
tive values, and predictive accuracy of life-threatening events
were also evaluated by standard methods. A value of p , 0.05
was considered statistically significant.
RESULTS
Life-threatening events and induced ventricular arrhyth-
mias. The characteristics of the 33 Brugada patients are
summarized in Table 1. Nineteen patients (58%) had a
history of life-threatening events defined as syncopal epi-
sodes (12 patients) and aborted sudden death (7 patients).
In nine of these patients, VF was documented before the
study. Eleven patients had a history of one or more family
members with sudden death of unknown etiology. In 15 of
19 patients with life-threatening events, malignant ventric-
ular arrhythmias were inducible by ventricular electrical
stimulation under with (five patients) or without (10 pa-
tients) the use of antiarrhythmic drugs (Fig. 2). Of these 15
patients, VF was inducible in 11 patients, and rapid,
nonsustained polymorphic VT in four patients. Eleven
patients with inducible VF or polymorphic VT received
subsequent implantation of a cardiac defibrillator. Of the
remaining four patients, two patients were treated with
either beta-blocker or amiodarone, and two patients had no
therapy. Although ventricular electrical stimulation was
performed in five patients with no symptomatic episodes,
none of these patients had inducible VF or polymorphic
VT.
Noninvasive determination test results. Individual test
results of the three noninvasive indices in the 33 patients are
shown in Table 1. In all patients, an RBBB pattern and
ST-segment elevation were present in the right chest leads
at the time of the tests, whereas they were absent in the left
lateral leads.
All of the study patients had interpretable test results for
LP. A representative example of a positive LP is shown in
Figure 3. Of the 33 patients, LP were present in 24 patients
(73%). Of 19 patients with life-threatening events, 17
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patients (89%) had documented LP. The mean RMS40 and
LAS40 were 15.4 6 10.4 mV and 46 6 11 ms, respectively.
An indeterminate TWA result was obtained in two of 33
patients due to extrasystoles during exercise testing. These
two patients were excluded from analysis for TWA, but they
were included in the assessment of LP and QTD. Of the 31
patients, the TWA was present in five patients (16%). The
mean alternans voltage in the VM lead was 1.18 6 1.67 mV.
The mean QTc and the mean QTcmax2QTcmin were
417 6 16 ms and 45 6 14 ms, respectively. The QTc was
Table 1. Comparison of Brugada Patient and Control Groups
Patient Group
(n 5 33)
Control Group
(n 5 30)
p
Value
Odds
Ratio
Age (mean 6 SD) (yrs) 45 6 14 43 6 9 NS
Gender, male 31 30 NS
Defined life-threatening events 19 (58%)
Syncope 12
Aborted sudden death 7
Documented VF 9 (27%)
Family history of sudden death 11 (33%)
Induction of ventricular arrhythmia in
patients with defined events
15/19 (79%)
VF 11
Polymorphic VT 4
Determinate LP 24 (73%) 1 (3%) ,0.0001 77.3
RMS40 (mV) 15.4 6 10.4 43.1 6 20.7 ,0.0001
LAS40 (ms) 46 6 11 29 6 7 ,0.0001
Determinate TWA 5/31 (16%) 2 (7%) NS 2.7
Alternans voltage in VM lead (mV) 1.18 6 1.67 0.98 6 1.81 NS
Increased QTD 9 (27%) 6 (20%) NS 1.5
Mean QTc (ms) 417 6 16 404 6 15 ,0.05
QTcmax2QTcmin (ms) 45 6 14 42 6 17 NS
LAS40 5 the duration of low-amplitude signals ,40 mV in the terminal filtered QRS; LP 5 late potentials; QTc 5 corrected
QT interval; QTcmax 5 maximal QTc; QTcmin 5 minimal QTc; QTD 5 QTc dispersion; RMS40 5 the root mean square
voltage of the terminal 40 ms in the filtered QRS; TWA 5 T-wave alternans; VF 5 ventricular fibrillation; VM 5 vector
magnitude; VT 5 ventricular tachycardia.
Figure 2. Polymorphic ventricular tachycardia generating into ventricular fibrillation induced by programmed electrical stimulation without the use of
antiarrhythmic drugs in a patient with Brugada syndrome and several syncopal episodes. This patient required cardioversion for termination of this rhythm.
HBE 5 His bundle electrogram; HRA 5 high right atrium; RVA 5 right ventricular apex.
1631JACC Vol. 37, No. 6, 2001 Ikeda et al.
May 2001:1628–34 Risk-Stratifying Patients With Brugada Syndrome
normal (,460 ms) (18) for all but one patient (462 ms). An
increased QTD (.50 ms) (17) was present in nine of 33
patients (27%). Differences in the three noninvasive indices
between the patient group and control group are shown in
Table 1. The incidence of LP-positive patients was signif-
icantly (p , 0.0001) higher in the patient group than in the
controls, showing a significant difference in the RMS40 and
LAS40. The odds ratio of the patient group compared with
the control group was 77.3. Incidences of TWA and
increased QTD were not significantly different between the
patient and the controls. Although the mean QTc of the
patient group was significantly (p , 0.05) greater than that
of the controls, the alternans voltage and QTcmax2QTcmin
were not significantly different.
Predictive values of the three indices for life-threatening
events. In the patient group, the values of three noninva-
sive indices for predicting life-threatening events are shown
in Table 2. Univariate analyses were performed to identify
patients at risk for life-threatening events. Occurrence of
life-threatening events was significantly higher in patients
with the presence of LP than in those without LP (p 5
0.017). Late potentials were found to be an independent
predictor of life-threatening events, whereas TWA and a
QTD .50 ms were not. Multivariate logistic regression
analysis was performed to test the statistical significance of
LP in predicting life-threatening events. Of the three
markers, the LP had the most significant relation to the
occurrence of life-threatening events (p 5 0.006). The
predictive values of LP, TWA, and QTD for occurrence of
life-threatening events are shown in Table 3. The LP
achieved the highest predictive accuracy (73%), and they
showed the highest sensitivity (89%) and negative predictive
value (78%). Although TWA and QTD had a higher
specificity (92% and 79%, respectively) than LP, the sensi-
tivity of TWA and QTD was quite low (22% and 32%,
respectively).
No relationship between LP and His-Purkinje conduction/
ST-segment elevation. The relationship between the pres-
ence of LP/the H-V interval at the time of electrophysi-
ologic investigation and between the presence of LP/the
maximal magnitude of J-point elevation in leads V1 through
V3 was evaluated. The mean H-V interval was 52 6 10 ms.
The mean maximal magnitude of ST-segment (J-point)
elevation in leads V1 through V3 was 0.31 6 0.1 mV. The
mean H-V interval was not significantly different between
the presence and the absence of LP (53 6 11 ms vs. 51 6
9 ms, respectively). The mean maximal magnitude of
J-point elevation was also not significantly different between
the presence and the absence of LP (0.32 6 0.1 mV vs.
0.3 6 0.09 mV, respectively). We also evaluated the
relationship between life-threatening events/inducibility
and the H-V interval/the magnitude of J-point elevation.
No relationship existed between their values.
DISCUSSION
Brugada syndrome has been recognized as a distinct clinical
entity characterized by an RBBB pattern and ST-segment
elevation in the right chest leads, a structurally normal heart,
and sudden cardiac death due to arrhythmic events. At
present, the role of conduction disturbance in the right
ventricle in arrhythmogenesis of the syndrome is a matter of
some controversy, whereas repolarization abnormalities
have been linked to malignant ventricular tachyarrhythmias
(3,4,6). Although the high incidence of LP detected by
signal-averaged ECG in Brugada syndrome is well known,
no studies have shown whether or not LP could serve as an
independent noninvasive technique to identify patients at
risk for life-threatening events in this syndrome.Table 2. Univariate and Multivariate Analyses of Three
Noninvasive Indices Associated With Life-Threatening Events
Indices
Univariate Analysis
Multivariate
Analysis
p
Value
Odds
Ratio
p
Value
Determinate LP 0.017 8.5 0.006
Determinate TWA 0.28 3.5 0.39
Increased QTD 0.4 1.7 0.88
LP 5 late potentials; QTD 5 corrected QT-interval dispersion; TWA 5 T-wave
alternans.
Table 3. Predictive Values of Three Noninvasive Indices
Associated With Life-Threatening Events
Sensitivity Specificity PPV NPV PA
Determinate LP 89% 50% 71% 78% 73%
Determinate TWA 22% 92% 80% 46% 52%
Increased QTD 32% 79% 67% 46% 52%
LP 5 late potentials; NPV 5 negative predictive value; PA 5 predictive accuracy;
PPV 5 positive predictive value; QTD 5 corrected QT-interval dispersion; TWA 5
T-wave alternans.
Figure 3. Electrocardiographic tracings in leads V1 through V3 and the
signal-averaged electrocardiogram for a patient with Brugada syndrome
and syncopal episodes. The late potentials, represented by the shaded area,
are positive, showing an RMS40 ,20 mV, and an LAS40 .38 ms.
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Conduction disturbance and life-threatening events.
Several clinical studies (7–10) in a small patient population
with Brugada syndrome have demonstrated that LP were
observed in most patients with documented VF. Kasanuki et
al. (8) studied five patients with idiopathic VF and struc-
turally normal hearts, compatible with this syndrome, using
signal-averaged ECG. All five patients had LP when the
characteristic ECG findings were present. The investigators
have also shown a conduction delay in the area between the
anterior wall and the septal region of the right ventricular
outflow tract using body surface mapping. In reports from
Nademanee et al. (7) and Kobayashi et al. (9), LP were
shown in 11 of 13 Brugada patients and in all 4 Brugada
patients studied, respectively. In the present study, we
assessed the presence of LP in a larger population (n 5 33)
with an RBBB pattern and ST-segment elevation in leads
V1 through V3 at time of the tests. Seventy-three percent of
the patients demonstrated the presence of LP. Of the 19
patients with a history of life-threatening events, 89% of
patients demonstrated LP. Univariate and multivariate anal-
yses revealed that the presence of LP is an independent
predictor of life-threatening events and had the most
significant relation to the occurrence of such events of the
three markers tested. Therefore, the presence of LP is a
noninvasive risk stratifier in patients with Brugada syn-
drome. To clarify the value of LP, a longer follow-up study
of these patients will be necessary.
Late potentials are abnormal low-amplitude signals in the
terminal portion of the QRS complex that reflect delayed
conduction of the ventricle. The value of LP in predicting
ventricular arrhythmias or sudden death has been demon-
strated in numerous previous studies of patients with struc-
turally abnormal hearts, especially in studies of patients after
myocardial infarction. In the postinfarct setting, the inci-
dence of LP ranges from 12% to 38% (11–13). Although
the hearts of patients with Brugada syndrome are structur-
ally normal, LP were observed with a high incidence (73%)
in our study. It is known that bundle branch block causes
delay and fragmentation of the electrical signal (i.e., LP) by
a different mechanism that is encountered with areas of
conduction block, while an impulse is transmitting through
the His bundle to the ventricles. Although our Brugada
patients had an RBBB pattern in the right chest leads for
the syndrome, no patients had a true RBBB (i.e., mimic
RBBB) because of an absence of a typical widened S-wave
and a wide QRS complex in the left lateral leads. In
addition, no association existed between the presence of LP
and the H-V interval. Therefore, the presence of LP is not
looking at an abnormally prolonged His-Purkinje conduc-
tion (RBBB) in our Brugada patients. In this study, all
patients had a significant ST-segment elevation for the
syndrome at the time of tests; however, 27% of patients had
an absence of LP, and no association existed between the
presence of LP and the magnitude of J-point elevation.
Also, the presence of LP may not be the mechanism
responsible for the observed ST-segment elevation in these
patients.
Repolarization abnormalities and life-threatening
events. Theoretical considerations and recent experiments
have suggested one possible mechanism for ST-segment
elevation in the early precordial leads and arrhythmogenesis
in the syndrome (i.e., repolarization abnormalities hypoth-
esis). Antzelevitch et al. (3,4,6) have proposed that
epicardial-endocardial heterogeneity of repolarization is re-
sponsible for the ST-segment elevation observed in patients
with the Brugada syndrome. Several studies (19–21) with
sodium channel blockers support their observations.
Recently, the presence of TWA or QTD (noninvasive
markers), which reflect repolarization abnormalities, has
been reported to be associated with an increased risk of
ventricular arrhythmias in several clinical settings (13–17).
No studies have demonstrated the clinical values of these
markers with respect to life-threatening events or malignant
ventricular arrhythmias in the setting of Brugada syndrome.
A case report (22) has demonstrated that a visual TWA was
observed during ST-segment elevation augmented by intra-
venous administration of a sodium channel blocker (ciben-
zoline) in a patient with Brugada syndrome. In the present
study, we assessed the value of two markers (TWA and
QTD) for identifying Brugada patients who are at risk for
life-threatening events by testing for inducible VF or
polymorphic VT. Our results suggest that TWA and QTD
are not independent predictors of life-threatening events,
despite the presence of ST-segment elevation at the time of
the tests. In addition, the values of both markers in the
patients were not different from those of normal individuals
matched for age and gender. Therefore, TWA and QTD,
both repolarization abnormality markers, are not useful for
identifying high-risk patients in the syndrome.
Study limitations. In the present study, we assessed only
LP, TWA, and QTD as noninvasive markers. For other
noninvasive markers such as heart rate variability (8,23), an
association with this syndrome is unknown. Our selected
noninvasive markers may be used to determine the full scope
of arrhythmogenic mechanisms underlying Brugada syn-
drome. Therefore, additional studies with different technol-
ogies will be necessary to confirm the conduction abnormal-
ity hypothesis in arrhythmogeneis of Brugada syndrome.
Brugada et al. (24) have reported that asymptomatic pa-
tients with the classic ECG abnormalities have the same
risk of arrhythmic events as do patients who have had an
episode of syncope or aborted sudden death. Unfortunately,
the present study did not include follow-up data in the
asymptomatic patients. Nademanee et al. (7) have demon-
strated that, during exercise, the ECG abnormalities asso-
ciated with this syndrome can disappear. For TWA mea-
surements, we used exercise testing. In our study
population, all patients had persistent ECG abnormalities
even during exercise testing because it was a low grade of
exercise.
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Clinical implications. In identifying patients at high risk
for sudden cardiac death due to VF and who may be
candidates for an implantable cardiac defibrillator, nonin-
vasive measurements are more desirable than invasive elec-
trophysiologic studies. As shown in our present study and
several previous studies (19,24–26), VF or polymorphic VT
can be occasionally induced by programmed ventricular
stimulation in these patients. Our study shows that detec-
tion of LP by signal-averaged ECG is a useful noninvasive
technique for identifying such patients because it signifi-
cantly predicts life-threatening events. Regarding the mech-
anism of arrhythmogenesis in this syndrome, our clinical
results may support the conduction abnormality hypothesis.
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